公开(公告)号：US20250009798A1

公开(公告)日：2025-01-09

申请号：US18708166

申请日：2022-11-07

Applicant: Baylor College of Medicine

Inventor： Nabil M. Ahmed ,  Jessica Morris ,  Ahmed Gad ,  Sujith Joseph

IPC: A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86 ,  C12N15/87

Abstract: Disclosed herein, in some aspects, are immune cells comprising one or more engineered antigen receptors and one or more non-canonical CD6 isoforms and/or canonical CD6. Also disclosed are methods for cancer treatment comprising administering such immune cells to a subject in need thereof. Further disclosed are nucleic acids encoding a chimeric antigen receptor and a non-canonical CD6 isoform, and cells harboring same.

公开(公告)号：US20250041341A1

公开(公告)日：2025-02-06

申请号：US18717357

申请日：2022-12-20

Applicant: Baylor College of Medicine

Inventor： Sujith Joseph ,  Nabil M. Ahmed ,  Meenakshi Hegde

IPC: A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/85

Abstract: Embodiments of the present disclosure include methods and compositions related to CD105-targeting polypeptides. In some aspects, disclosed are chimeric receptors engineered to bind to CD105. Cells (e.g., NK cells, T-cells) expressing CD105-targeting peptides are described. Also described are therapeutic methods using polypeptides of the disclosure.